Reversible, interrelated mRNA and miRNA expression patterns in the transcriptome of Rasless fibroblasts: Functional and mechanistic implications

BMC Genomics

Volumn 14, Issue 1, 2013, Pages

  Azrak, Sami S ^a   Ginel Picardo, Alicia ^a   Drosten, Matthias ^b   Barbacid, Mariano ^b   Santos, Eugenio ^a  

^a CSIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Cell cycle; Differential gene expression; HRAS; KRAS; miRNA; mRNA; NRAS; Ras; Transcriptional responses; Transcriptome

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; DNA; K RAS PROTEIN; MESSENGER RNA; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MYC PROTEIN; PROTEIN MIR 106A; PROTEIN MIR 106B; PROTEIN MIR 17; PROTEIN MIR 183; PROTEIN MIR 212; PROTEIN MIR 335; PROTEIN P53; RETINOBLASTOMA PROTEIN; RNA; TRANSCRIPTION FACTOR E2F; TRANSCRIPTOME; UNCLASSIFIED DRUG; BRAF PROTEIN, MOUSE; MAP2K1 PROTEIN, MOUSE; RAS PROTEIN;

ANIMAL CELL; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DIVISION; CELL PROLIFERATION; CELLULAR STRESS RESPONSE; DNA DAMAGE; EMBRYO; FIBROBLAST; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE REPRESSION; GENETIC TRANSCRIPTION; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PHENOTYPE; PLEIOTROPY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RNA ANALYSIS; RNA PROCESSING; RNA TRANSCRIPTION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CLUSTER ANALYSIS; G1 PHASE CELL CYCLE CHECKPOINT; GENETICS; METABOLISM;

ANIMALS; CLUSTER ANALYSIS; DNA DAMAGE; FIBROBLASTS; G1 PHASE CELL CYCLE CHECKPOINTS; MAP KINASE KINASE 1; MICE; MICRORNAS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RNA, MESSENGER; TRANSCRIPTOME;

EID: 84886228790     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-14-731     Document Type: Article

References (115)

1. Castellano E, Santos E. Functional specificity of ras isoforms: so similar but so different. Genes Cancer 2011, 2:216-231. 10.1177/1947601911408081, 3128637, 21779495.
2. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008, 9:517-531. 10.1038/nrm2438, 18568040.
3. Rojas JM, Oliva JL, Santos E. Mammalian son of sevenless Guanine nucleotide exchange factors: old concepts and new perspectives. Genes Cancer 2011, 2:298-305. 10.1177/1947601911408078, 3128634, 21779500.
4. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003, 3:11-22.
5. Leon J, Guerrero I, Pellicer A. Differential expression of the ras gene family in mice. Mol Cell Biol 1987, 7:1535-1540. 365242, 3600635.
6. Fiorucci G, Hall A. All three human ras genes are expressed in a wide range of tissues. Biochim Biophys Acta 1988, 950:81-83. 10.1016/0167-4781(88)90076-0, 3282543.
7. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989, 49:4682-4689.
8. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003, 3:459-465. 10.1038/nrc1097, 12778136.
9. Fernandez-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer 2011, 2:344-358. 10.1177/1947601911411084, 3128640, 21779504.
10. Hancock JF. Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol 2003, 4:373-384. 10.1038/nrm1105, 12728271.
11. Matallanas D, Sanz-Moreno V, Arozarena I, Calvo F, Agudo-Ibanez L, Santos E, Berciano MT, Crespo P. Distinct utilization of effectors and biological outcomes resulting from site-specific Ras activation: Ras functions in lipid rafts and Golgi complex are dispensable for proliferation and transformation. Mol Cell Biol 2006, 26:100-116. 10.1128/MCB.26.1.100-116.2006, 1317613, 16354683.
12. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol 2000, 10:147-154. 10.1016/S0962-8924(00)01740-2, 10740269.
13. Esteban LM, Vicario-Abejon C, Fernandez-Salguero P, Fernandez-Medarde A, Swaminathan N, Yienger K, Lopez E, Malumbres M, McKay R, Ward JM, et al. Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol Cell Biol 2001, 21:1444-1452. 10.1128/MCB.21.5.1444-1452.2001, 86690, 11238881.
14. Plowman SJ, Williamson DJ, O'Sullivan MJ, Doig J, Ritchie AM, Harrison DJ, Melton DW, Arends MJ, Hooper ML, Patek CE. While K-ras is essential for mouse development, expression of the K-ras 4A splice variant is dispensable. Mol Cell Biol 2003, 23:9245-9250. 10.1128/MCB.23.24.9245-9250.2003, 309700, 14645534.
15. Umanoff H, Edelmann W, Pellicer A, Kucherlapati R. The murine N-ras gene is not essential for growth and development. Proc Natl Acad Sci USA 1995, 92:1709-1713. 10.1073/pnas.92.5.1709, 42589, 7878045.
16. Johnson L, Greenbaum D, Cichowski K, Mercer K, Murphy E, Schmitt E, Bronson RT, Umanoff H, Edelmann W, Kucherlapati R, Jacks T. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev 1997, 11:2468-2481. 10.1101/gad.11.19.2468, 316567, 9334313.
17. Koera K, Nakamura K, Nakao K, Miyoshi J, Toyoshima K, Hatta T, Otani H, Aiba A, Katsuki M. K-ras is essential for the development of the mouse embryo. Oncogene 1997, 15:1151-1159. 10.1038/sj.onc.1201284, 9294608.
18. Potenza N, Vecchione C, Notte A, De Rienzo A, Rosica A, Bauer L, Affuso A, De Felice M, Russo T, Poulet R, et al. Replacement of K-Ras with H-Ras supports normal embryonic development despite inducing cardiovascular pathology in adult mice. EMBO Rep 2005, 6:432-437. 10.1038/sj.embor.7400397, 1299307, 15864294.
19. Drosten M, Dhawahir A, Sum EY, Urosevic J, Lechuga CG, Esteban LM, Castellano E, Guerra C, Santos E, Barbacid M. Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J 2010, 29:1091-1104. 10.1038/emboj.2010.7, 2845279, 20150892.
20. Castellano E, De Las Rivas J, Guerrero C, Santos E. Transcriptional networks of knockout cell lines identify functional specificities of H-Ras and N-Ras: significant involvement of N-Ras in biotic and defense responses. Oncogene 2007, 26:917-933. 10.1038/sj.onc.1209845, 16909116.
21. Castellano E, Guerrero C, Nunez A, De Las Rivas J, Santos E. Serum-dependent transcriptional networks identify distinct functional roles for H-Ras and N-Ras during initial stages of the cell cycle. Genome Biol 2009, 10:R123. 10.1186/gb-2009-10-11-r123, 3091317, 19895680.
22. Roberts ML, Drosopoulos KG, Vasileiou I, Stricker M, Taoufik E, Maercker C, Guialis A, Alexis MN, Pintzas A. Microarray analysis of the differential transformation mediated by Kirsten and Harvey Ras oncogenes in a human colorectal adenocarcinoma cell line. Int J Cancer 2006, 118:616-627. 10.1002/ijc.21386, 16152623.
23. Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, Ladd-Acosta C, Mesirov J, Golub TR, Jacks T. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet 2005, 37:48-55.
24. Vasseur S, Malicet C, Calvo EL, Labrie C, Berthezene P, Dagorn JC, Iovanna JL. Gene expression profiling by DNA microarray analysis in mouse embryonic fibroblasts transformed by rasV12 mutated protein and the E1A oncogene. Mol Cancer 2003, 2:19. 10.1186/1476-4598-2-19, 153489, 12685932.
25. Kim S, Lee YZ, Kim YS, Bahk YY. A Proteomic approach for protein-profiling the oncogenic ras induced transformation (H-, K-, and N-Ras) in NIH/3T3 mouse embryonic fibroblasts. Proteomics 2008, 8:3082-3093. 10.1002/pmic.200800106, 18601226.
26. Croonquist PA, Linden MA, Zhao F, Van Ness BG. Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells. Blood 2003, 102:2581-2592. 10.1182/blood-2003-04-1227, 12791645.
27. Gille H, Downward J. Multiple ras effector pathways contribute to G(1) cell cycle progression. J Biol Chem 1999, 274:22033-22040. 10.1074/jbc.274.31.22033, 10419529.
28. Stacey D, Kazlauskas A. Regulation of Ras signaling by the cell cycle. Curr Opin Genet Dev 2002, 12:44-46. 10.1016/S0959-437X(01)00262-3, 11790553.
29. Jones SM, Kazlauskas A. Growth-factor-dependent mitogenesis requires two distinct phases of signalling. Nat Cell Biol 2001, 3:165-172. 10.1038/35055073, 11175749.
30. Coleman ML, Marshall CJ, Olson MF. RAS and RHO GTPases in G1-phase cell-cycle regulation. Nat Rev Mol Cell Biol 2004, 5:355-366.
31. Holmes C, Stanford WL. Concise review: stem cell antigen-1: expression, function, and enigma. Stem Cells 2007, 25:1339-1347. 10.1634/stemcells.2006-0644, 17379763.
32. Batts TD, Machado HL, Zhang Y, Creighton CJ, Li Y, Rosen JM. Stem cell antigen-1 (sca-1) regulates mammary tumor development and cell migration. PLoS One 2011, 6:e27841. 10.1371/journal.pone.0027841, 3226565, 22140470.
33. Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, Trumpp A. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009, 458:904-908. 10.1038/nature07815, 19212321.
34. Mitchell PO, Mills T, O'Connor RS, Kline ER, Graubert T, Dzierzak E, Pavlath GK. Sca-1 negatively regulates proliferation and differentiation of muscle cells. Dev Biol 2005, 283:240-252. 10.1016/j.ydbio.2005.04.016, 15901485.
35. Ishida S, Huang E, Zuzan H, Spang R, Leone G, West M, Nevins JR. Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol 2001, 21:4684-4699. 10.1128/MCB.21.14.4684-4699.2001, 87143, 11416145.
36. Ma Y, Croxton R, Moorer RL, Cress WD. Identification of novel E2F1-regulated genes by microarray. Arch Biochem Biophys 2002, 399:212-224. 10.1006/abbi.2002.2761, 11888208.
37. Blais A, Dynlacht BD. Hitting their targets: an emerging picture of E2F and cell cycle control. Curr Opin Genet Dev 2004, 14:527-532. 10.1016/j.gde.2004.07.003, 15380244.
38. Soucek L, Whitfield JR, Sodir NM, Masso-Valles D, Serrano E, Karnezis AN, Swigart LB, Evan GI. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev 2013, 27:504-513. 10.1101/gad.205542.112, 3605464, 23475959.
39. Aktas H, Cai H, Cooper GM. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. Mol Cell Biol 1997, 17:3850-3857. 232237, 9199319.
40. Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 2000, 14:2393-2409. 10.1101/gad.813200, 11018009.
41. D'Abaco GM, Hooper S, Paterson H, Marshall CJ. Loss of Rb overrides the requirement for ERK activity for cell proliferation. J Cell Sci 2002, 115:4607-4616. 10.1242/jcs.00161, 12415005.
42. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008, 9:402-412. 10.1038/nrm2395, 18431400.
43. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007, 8:275-283. 10.1038/nrm2147, 17380161.
44. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259-269.
45. Spizzo R, Nicoloso MS, Croce CM, Calin GA. SnapShot: MicroRNAs in Cancer. Cell 2009, 137:586-e581. 10.1016/j.cell.2009.04.040, 19410551.
46. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med 2009, 60:167-179. 10.1146/annurev.med.59.053006.104707, 19630570.
47. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. RAS is regulated by the let-7 microRNA family. Cell 2005, 120:635-647. 10.1016/j.cell.2005.01.014, 15766527.
48. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004, 64:3753-3756. 10.1158/0008-5472.CAN-04-0637, 15172979.
49. Osada H, Takahashi T. let-7 and miR-17-92: small-sized major players in lung cancer development. Cancer Sci 2011, 102:9-17. 10.1111/j.1349-7006.2010.01707.x, 20735434.
50. Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell 2008, 133:217-222. 10.1016/j.cell.2008.04.001, 2732113, 18423194.
51. Fassina A, Marino F, Siri M, Zambello R, Ventura L, Fassan M, Simonato F, Cappellesso R. The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies. Lab Invest 2012, 92:1574-1582. 10.1038/labinvest.2012.129, 22964854.
52. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004, 101:11755-11760. 10.1073/pnas.0404432101, 511048, 15284443.
53. Tagawa H, Seto M. A microRNA cluster as a target of genomic amplification in malignant lymphoma. Leukemia 2005, 19:2013-2016. 10.1038/sj.leu.2403942, 16167061.
54. Gordon AT, Brinkschmidt C, Anderson J, Coleman N, Dockhorn-Dworniczak B, Pritchard-Jones K, Shipley J. A novel and consistent amplicon at 13q31 associated with alveolar rhabdomyosarcoma. Genes Chromosomes Cancer 2000, 28:220-226. 10.1002/(SICI)1098-2264(200006)28:2<220::AID-GCC11>3.0.CO;2-T, 10825007.
55. Schmidt H, Bartel F, Kappler M, Wurl P, Lange H, Bache M, Holzhausen HJ, Taubert H. Gains of 13q are correlated with a poor prognosis in liposarcoma. Mod Pathol 2005, 18:638-644. 10.1038/modpathol.3800326, 15540119.
56. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y, Takahashi T. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005, 65:9628-9632. 10.1158/0008-5472.CAN-05-2352, 16266980.
57. Landais S, Landry S, Legault P, Rassart E. Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia. Cancer Res 2007, 67:5699-5707. 10.1158/0008-5472.CAN-06-4478, 17575136.
58. Cascio S, D'Andrea A, Ferla R, Surmacz E, Gulotta E, Amodeo V, Bazan V, Gebbia N, Russo A. miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J Cell Physiol 2010, 224:242-249.
59. Catela Ivkovic T, Aralica G, Cacev T, Loncar B, Kapitanovic S. miR-106a overexpression and pRB downregulation in sporadic colorectal cancer. Exp Mol Pathol 2013, 94:148-154. 10.1016/j.yexmp.2012.11.002, 23178825.
60. Wang Z, Liu M, Zhu H, Zhang W, He S, Hu C, Quan L, Bai J, Xu N. miR-106a Is frequently upregulated in gastric cancer and inhibits the extrinsic apoptotic pathway by targeting FAS. Mol Carcinog 2012, 52:634-646.
61. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A, Fedele G, et al. Identification of the miR-106b 25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal 2010, 3:ra29. 10.1126/scisignal.2000594, 2982149, 20388916.
62. Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, Iliopoulos D, Pilozzi E, Liu CG, Negrini M, et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 2008, 13:272-286. 10.1016/j.ccr.2008.02.013, 18328430.
63. Li Y, Tan W, Neo TW, Aung MO, Wasser S, Lim SG, Tan TM. Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci 2009, 100:1234-1242. 10.1111/j.1349-7006.2009.01164.x, 19486339.
64. Razumilava N, Bronk SF, Smoot RL, Fingas CD, Werneburg NW, Roberts LR, Mott JL. miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Hepatology 2012, 55:465-475. 10.1002/hep.24698, 3268937, 21953056.
65. Suh SS, Yoo JY, Nuovo GJ, Jeon YJ, Kim S, Lee TJ, Kim T, Bakacs A, Alder H, Kaur B, et al. MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme. Proc Natl Acad Sci U S A 2012, 109:5316-5321. 10.1073/pnas.1202465109, 3325690, 22431589.
66. Park JK, Henry JC, Jiang J, Esau C, Gusev Y, Lerner MR, Postier RG, Brackett DJ, Schmittgen TD. miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. Biochem Biophys Res Commun 2011, 406:518-523. 10.1016/j.bbrc.2011.02.065, 3069485, 21329664.
67. Li Y, Zhang D, Chen C, Ruan Z, Huang Y. MicroRNA-212 displays tumor-promoting properties in non-small cell lung cancer cells and targets the hedgehog pathway receptor PTCH1. Mol Biol Cell 2012, 23:1423-1434. 10.1091/mbc.E11-09-0777, 3327317, 22357618.
68. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, Lund E, Dahlberg JE. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 2005, 102:3627-3632. 10.1073/pnas.0500613102, 552785, 15738415.
69. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 2005, 102:19075-19080. 10.1073/pnas.0509603102, 1323209, 16365291.
70. Weeraratne SD, Amani V, Teider N, Pierre-Francois J, Winter D, Kye MJ, Sengupta S, Archer T, Remke M, Bai AH, et al. Pleiotropic effects of miR-183 96 182 converge to regulate cell survival, proliferation and migration in medulloblastoma. Acta Neuropathol 2012, 123:539-552. 10.1007/s00401-012-0969-5, 22402744.
71. Zhu W, Liu X, He J, Chen D, Hunag Y, Zhang YK. Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study. BMC Cancer 2011, 11:393. 10.1186/1471-2407-11-393, 3183044, 21920043.
72. Song L, Liu L, Wu Z, Li Y, Ying Z, Lin C, Wu J, Hu B, Cheng SY, Li M, Li J. TGF-beta induces miR-182 to sustain NF-kappaB activation in glioma subsets. J Clin Invest 2012, 122:3563-3578. 10.1172/JCI62339, 3589141, 23006329.
73. Yan Z, Xiong Y, Xu W, Gao J, Cheng Y, Wang Z, Chen F, Zheng G. Identification of hsa-miR-335 as a prognostic signature in gastric cancer. PLoS One 2012, 7:e40037. 10.1371/journal.pone.0040037, 3388997, 22802949.
74. Jiang J, Sun X, Wang W, Jin X, Bo X, Li Z, Bian A, Jiu J, Wang X, Liu D, et al. Tumor microRNA-335 expression is associated with poor prognosis in human glioma. Med Oncol 2012, 29:3472-3477. 10.1007/s12032-012-0259-z, 22644918.
75. Li QJ, Chau J, Ebert PJ, Sylvester G, Min H, Liu G, Braich R, Manoharan M, Soutschek J, Skare P, et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 2007, 129:147-161. 10.1016/j.cell.2007.03.008, 17382377.
76. Wang X, Gocek E, Liu CG, Studzinski GP. MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3. Cell Cycle 2009, 8:736-741. 10.4161/cc.8.5.7870, 2804747, 19221487.
77. Urbich C, Kaluza D, Fromel T, Knau A, Bennewitz K, Boon RA, Bonauer A, Doebele C, Boeckel JN, Hergenreider E, et al. MicroRNA-27a/b controls endothelial cell repulsion and angiogenesis by targeting semaphorin 6A. Blood 2012, 119:1607-1616. 10.1182/blood-2011-08-373886, 22184411.
78. Bridge G, Monteiro R, Henderson S, Emuss V, Lagos D, Georgopoulou D, Patient R, Boshoff C. The microRNA-30 family targets DLL4 to modulate endothelial cell behavior during angiogenesis. Blood 2012, 120:5063-5072. 10.1182/blood-2012-04-423004, 23086751.
79. Tanic M, Yanowsky K, Rodriguez-Antona C, Andres R, Marquez-Rodas I, Osorio A, Benitez J, Martinez-Delgado B. Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene. PLoS One 2012, 7:e38847. 10.1371/journal.pone.0038847, 3372467, 22701724.
80. Yang JH, Li JH, Shao P, Zhou H, Chen YQ, Qu LH. starBase: a database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data. Nucleic Acids Res 2011, 39:D202-D209. 10.1093/nar/gkq1056, 3013664, 21037263.
81. Hackl M, Brunner S, Fortschegger K, Schreiner C, Micutkova L, Muck C, Laschober GT, Lepperdinger G, Sampson N, Berger P, et al. miR-17, miR-19b, miR-20a, and miR-106a are down-regulated in human aging. Aging Cell 2010, 9:291-296. 10.1111/j.1474-9726.2010.00549.x, 2848978, 20089119.
82. Wu N, Sulpice E, Obeid P, Benzina S, Kermarrec F, Combe S, Gidrol X. The miR-17 family links p63 protein to MAPK signaling to promote the onset of human keratinocyte differentiation. PLoS One 2012, 7:e45761. 10.1371/journal.pone.0045761, 3454365, 23029228.
83. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435:839-843. 10.1038/nature03677, 15944709.
84. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 2002, 3:11-20.
85. Sylvestre Y, De Guire V, Querido E, Mukhopadhyay UK, Bourdeau V, Major F, Ferbeyre G, Chartrand P. An E2F/miR-20a autoregulatory feedback loop. J Biol Chem 2007, 282:2135-2143.
86. Woods K, Thomson JM, Hammond SM. Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J Biol Chem 2007, 282:2130-2134.
87. Diosdado B, van de Wiel MA, Terhaar Sive Droste JS, Mongera S, Postma C, Meijerink WJ, Carvalho B, Meijer GA. MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br J Cancer 2009, 101:707-714. 10.1038/sj.bjc.6605037, 2736819, 19672269.
88. Rinaldi A, Poretti G, Kwee I, Zucca E, Catapano CV, Tibiletti MG, Bertoni F. Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma. Leuk Lymphoma 2007, 48:410-412. 10.1080/10428190601059738, 17325905.
89. Conkrite K, Sundby M, Mukai S, Thomson JM, Mu D, Hammond SM, MacPherson D. miR-17 92 cooperates with RB pathway mutations to promote retinoblastoma. Genes Dev 2011, 25:1734-1745. 10.1101/gad.17027411, 3165937, 21816922.
90. Nittner D, Lambertz I, Clermont F, Mestdagh P, Kohler C, Nielsen SJ, Jochemsen A, Speleman F, Vandesompele J, Dyer MA, et al. Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation. Nat Cell Biol 2012, 14:958-965. 10.1038/ncb2556, 22864477.
91. Petrocca F, Vecchione A, Croce CM. Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res 2008, 68:8191-8194. 10.1158/0008-5472.CAN-08-1768, 18922889.
92. Thangavel C, Boopathi E, Ertel A, Lim M, Addya S, Fortina P, Witkiewicz AK, Knudsen ES. Regulation of miR106b cluster through the RB pathway: Mechanism and functional targets. Cell Cycle 2013, 12:98-111. 10.4161/cc.23029, 23255112.
93. Ivanovska I, Ball AS, Diaz RL, Magnus JF, Kibukawa M, Schelter JM, Kobayashi SV, Lim L, Burchard J, Jackson AL, et al. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol 2008, 28:2167-2174. 10.1128/MCB.01977-07, 2268421, 18212054.
94. Kan T, Sato F, Ito T, Matsumura N, David S, Cheng Y, Agarwal R, Paun BC, Jin Z, Olaru AV, et al. The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. Gastroenterology 2009, 136:1689-1700. 10.1053/j.gastro.2009.02.002, 2887605, 19422085.
95. Wang Z, Liu M, Zhu H, Zhang W, He S, Hu C, Quan L, Bai J, Xu N. Suppression of p21 by c-Myc through members of miR-17 family at the post-transcriptional level. Int J Oncol 2010, 37:1315-1321.
96. Zhang H, Zuo Z, Lu X, Wang L, Wang H, Zhu Z. MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer. Oncol Rep 2012, 27:594-598.
97. Kumar M, Lu Z, Takwi AA, Chen W, Callander NS, Ramos KS, Young KH, Li Y. Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene 2011, 30:843-853. 10.1038/onc.2010.457, 3021102, 20935678.
98. Zhang CZ, Zhang JX, Zhang AL, Shi ZD, Han L, Jia ZF, Yang WD, Wang GX, Jiang T, You YP, et al. MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer 2010, 9:229. 10.1186/1476-4598-9-229, 2939570, 20813046.
99. Zhang J, Han L, Ge Y, Zhou X, Zhang A, Zhang C, Zhong Y, You Y, Pu P, Kang C. miR-221/222 promote malignant progression of glioma through activation of the Akt pathway. Int J Oncol 2010, 36:913-920.
100. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009, 16:498-509. 10.1016/j.ccr.2009.10.014, 2796583, 19962668.
101. Li G, Luna C, Qiu J, Epstein DL, Gonzalez P. Alterations in microRNA expression in stress-induced cellular senescence. Mech Ageing Dev 2009, 130:731-741. 10.1016/j.mad.2009.09.002, 2795064, 19782699.
102. Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P, Muschel RJ, Beech J, Kulshrestha R, Abdelmohsen K, Weinstock DM, et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 2011, 41:210-220. 10.1016/j.molcel.2010.12.005, 3249932, 21195000.
103. Wang XF, Shi ZM, Wang XR, Cao L, Wang YY, Zhang JX, Yin Y, Luo H, Kang CS, Liu N, et al. MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2. J Cancer Res Clin Oncol 2012, 138:573-584. 10.1007/s00432-011-1114-x, 22207524.
104. Shi L, Jiang D, Sun G, Wan Y, Zhang S, Zeng Y, Pan T, Wang Z. miR-335 promotes cell proliferation by directly targeting Rb1 in meningiomas. J Neurooncol 2012, 110:155-162. 10.1007/s11060-012-0951-z, 22886530.
105. Lynch J, Fay J, Meehan M, Bryan K, Watters KM, Murphy DM, Stallings RL. MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-beta signalling pathway. Carcinogenesis 2012, 33:976-985. 10.1093/carcin/bgs114, 3334516, 22382496.
106. Scarola M, Schoeftner S, Schneider C, Benetti R. miR-335 directly targets Rb1 (pRb/p105) in a proximal connection to p53-dependent stress response. Cancer Res 2010, 70:6925-6933. 10.1158/0008-5472.CAN-10-0141, 20713524.
107. Heyn H, Engelmann M, Schreek S, Ahrens P, Lehmann U, Kreipe H, Schlegelberger B, Beger C. MicroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development. Int J Cancer 2011, 129:2797-2806. 10.1002/ijc.25962, 21618216.
108. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264. 10.1093/biostatistics/4.2.249, 12925520.
109. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98:5116-5121. 10.1073/pnas.091062498, 33173, 11309499.
110. Murtagh F. Multidimensional clustering algorithms 1985, Wuerzburg: Physica-Verlag, COMPSTAT Lectures Volume 4.
111. Nogales-Cadenas R, Carmona-Saez P, Vazquez M, Vicente C, Yang X, Tirado F, Carazo JM, Pascual-Montano A. GeneCodis: interpreting gene lists through enrichment analysis and integration of diverse biological information. Nucleic Acids Res 2009, 37:W317-W322. 10.1093/nar/gkp416, 2703901, 19465387.
112. Tabas-Madrid D, Nogales-Cadenas R, Pascual-Montano A. GeneCodis3: a non-redundant and modular enrichment analysis tool for functional genomics. Nucleic Acids Res 2012, 40:W478-W483. 10.1093/nar/gks402, 3394297, 22573175.
113. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc 1995, 57:289. 300.
114. Oliveros JC. VENNY. An interactive tool for comparing lists with Venn Diagrams 2007, http://bioinfogp.cnb.csic.es/tools/venny/.
115. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45. 10.1093/nar/29.9.e45, 55695, 11328886.